Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias

[1]  L. Altucci,et al.  DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment , 2019, Epigenetics.

[2]  S. Armstrong,et al.  A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia , 2019, Blood.

[3]  E. Nevedomskaya,et al.  Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia , 2019, Journal of Hematology & Oncology.

[4]  Chun-Wei Chen,et al.  Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions , 2019, Front. Cell Dev. Biol..

[5]  C. Lim,et al.  Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention , 2019, British Journal of Cancer.

[6]  J. Bewersdorf,et al.  Epigenetic therapy combinations in acute myeloid leukemia: what are the options? , 2019, Therapeutic advances in hematology.

[7]  A. Shilatifard,et al.  Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia , 2018, Genes & development.

[8]  S. Armstrong,et al.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. , 2018, Blood.

[9]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[10]  F. Nigsch,et al.  Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia , 2017, Leukemia.

[11]  S. A. Ganai,et al.  Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders. , 2016, Pharmacology & therapeutics.

[12]  E. Yang,et al.  Revisiting Non-Cancer Drugs for Cancer Therapy. , 2016, Current topics in medicinal chemistry.

[13]  O. Schilling,et al.  Taspase1: a 'misunderstood' protease with translational cancer relevance , 2016, Oncogene.

[14]  T. Pandita,et al.  The many faces of histone H3K79 methylation. , 2016, Mutation research. Reviews in mutation research.

[15]  Manuel M Müller,et al.  Evidence that ubiquitylated H2B corrals hDot1L on the nucleosomal surface to induce H3K79 methylation , 2016, Nature Communications.

[16]  Sanjay Gupta,et al.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? , 2015, World journal of biological chemistry.

[17]  John G Doench,et al.  DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia , 2015, Nature Medicine.

[18]  P. Houghton,et al.  Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia , 2015, Clinical Cancer Research.

[19]  Michael G. Poirier,et al.  Post-Translational Modifications of Histones That Influence Nucleosome Dynamics , 2014, Chemical reviews.

[20]  J. Hsieh,et al.  Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis , 2014, Cell Research.

[21]  E. Olhava,et al.  DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[22]  S. Keeney,et al.  Dynamics of DOT1L localization and H3K79 methylation during meiotic prophase I in mouse spermatocytes , 2014, Chromosoma.

[23]  Robert A Copeland,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[24]  K. Zhao,et al.  Methylation of Histone H3 on Lysine 79 Associates with a Group of Replication Origins and Helps Limit DNA Replication Once per Cell Cycle , 2013, PLoS genetics.

[25]  D. Moazed,et al.  Heterochromatin protein Sir3 induces contacts between the amino terminus of histone H4 and nucleosomal DNA , 2013, Proceedings of the National Academy of Sciences.

[26]  F. van Leeuwen,et al.  Dot1-Dependent Histone H3K79 Methylation Promotes Activation of the Mek1 Meiotic Checkpoint Effector Kinase by Regulating the Hop1 Adaptor , 2013, PLoS genetics.

[27]  J. M. Arteaga-Salas,et al.  DOT1A-dependent H3K76 methylation is required for replication regulation in Trypanosoma brucei , 2012, Nucleic acids research.

[28]  Todd D. Westergard,et al.  A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. , 2012, Cancer research.

[29]  Jong-Wan Park,et al.  Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation* , 2011, The Journal of Biological Chemistry.

[30]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[31]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[32]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[33]  Yi Zhang,et al.  The diverse functions of Dot1 and H3K79 methylation. , 2011, Genes & development.

[34]  Yi Zhang,et al.  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.

[35]  Andrew J. Bannister,et al.  Regulation of chromatin by histone modifications , 2011, Cell Research.

[36]  N. Zeleznik-Le,et al.  Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. , 2010, Cancer research.

[37]  Han Liu,et al.  Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. , 2010, Cancer research.

[38]  S. Kron,et al.  Dissection of Rad9 BRCT domain function in the mitotic checkpoint response to telomere uncapping. , 2009, DNA repair.

[39]  C. Bach,et al.  Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia , 2009, PLoS biology.

[40]  H. Madhani,et al.  Nonredundant Requirement for Multiple Histone Modifications for the Early Anaphase Release of the Mitotic Exit Regulator Cdc14 from Nucleolar Chromatin , 2009, PLoS genetics.

[41]  M. Covic,et al.  Connection between histone H2A variants and chromatin remodeling complexes. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[42]  E. Li,et al.  The Histone H3K79 Methyltransferase Dot1L Is Essential for Mammalian Development and Heterochromatin Structure , 2008, PLoS genetics.

[43]  P. San-Segundo,et al.  Role of Dot1 in the Response to Alkylating DNA Damage in Saccharomyces cerevisiae: Regulation of DNA Damage Tolerance by the Error-Prone Polymerases Polζ/Rev1 , 2008, Genetics.

[44]  P. Secchiero,et al.  The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. , 2008, Current pharmaceutical design.

[45]  David Lydall,et al.  Histone methyltransferase Dot1 and Rad9 inhibit single-stranded DNA accumulation at DSBs and uncapped telomeres , 2008, The EMBO journal.

[46]  S. Kageyama,et al.  Changes in H3K79 Methylation During Preimplantation Development in Mice , 2008, Biology of reproduction.

[47]  Christopher R. Vakoc,et al.  DOT1L/KMT4 Recruitment and H3K79 Methylation Are Ubiquitously Coupled with Gene Transcription in Mammalian Cells , 2008, Molecular and Cellular Biology.

[48]  Song Tan,et al.  Interplay of chromatin modifiers on a short basic patch of histone H4 tail defines the boundary of telomeric heterochromatin. , 2007, Molecular cell.

[49]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[50]  Zhenhua Zhang,et al.  Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. , 2007, Cancer research.

[51]  Ian M. Fingerman,et al.  A charge-based interaction between histone H4 and Dot1 is required for H3K79 methylation and telomere silencing: identification of a new trans-histone pathway. , 2007, Genes & development.

[52]  J. Côté,et al.  Histone modifications in response to DNA damage. , 2007, Mutation research.

[53]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[54]  Todd D. Westergard,et al.  Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. , 2006, Genes & development.

[55]  Yi Zhang,et al.  Leukaemic transformation by CALM–AF10 involves upregulation of Hoxa5 by hDOT1L , 2006, Nature Cell Biology.

[56]  G. Cross,et al.  Selective di- or trimethylation of histone H3 lysine 76 by two DOT1 homologs is important for cell cycle regulation in Trypanosoma brucei. , 2006, Molecular cell.

[57]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[58]  S. Korsmeyer,et al.  Uncleaved TFIIA Is a Substrate for Taspase 1 and Active in Transcription , 2006, Molecular and Cellular Biology.

[59]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[60]  Robert Wysocki,et al.  Role of Dot1-Dependent Histone H3 Methylation in G1 and S Phase DNA Damage Checkpoint Functions of Rad9 , 2005, Molecular and Cellular Biology.

[61]  Megan F. Cole,et al.  Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast , 2005, Cell.

[62]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[63]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[64]  V. Honti,et al.  Characterization of the grappa Gene, the Drosophila Histone H3 Lysine 79 Methyltransferase , 2005, Genetics.

[65]  Tom J. Petty,et al.  Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks , 2004, Nature.

[66]  J. Hess.  MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.

[67]  Charles Kooperberg,et al.  The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. , 2004, Genes & development.

[68]  S. Korsmeyer,et al.  Taspase1 A Threonine Aspartase Required for Cleavage of MLL and Proper HOX Gene Expression , 2003, Cell.

[69]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[70]  K. Struhl,et al.  Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: A potential mechanism for position-effect variegation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Kevin Struhl,et al.  Ubiquitination of Histone H2B by Rad6 Is Required for Efficient Dot1-mediated Methylation of Histone H3 Lysine 79* , 2002, The Journal of Biological Chemistry.

[72]  G. Poirier,et al.  Disruptor of Telomeric Silencing-1 Is a Chromatin-specific Histone H3 Methyltransferase* , 2002, The Journal of Biological Chemistry.

[73]  Brian D. Strahl,et al.  Gene silencing: Trans-histone regulatory pathway in chromatin , 2002, Nature.

[74]  Zu-Wen Sun,et al.  Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast , 2002, Nature.

[75]  Kevin Struhl,et al.  Methylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain , 2002, Current Biology.

[76]  Kevin Struhl,et al.  Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. , 2002, Genes & development.

[77]  Philip R. Gafken,et al.  Dot1p Modulates Silencing in Yeast by Methylation of the Nucleosome Core , 2002, Cell.

[78]  M. Cleary,et al.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins , 2001, Oncogene.

[79]  M. Weber,et al.  Low-dose combination therapy: an important first-line treatment in the management of hypertension. , 2001, American journal of hypertension.

[80]  G. Roeder,et al.  Role for the silencing protein Dot1 in meiotic checkpoint control. , 2000, Molecular biology of the cell.

[81]  D. Gottschling,et al.  Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. , 1998, Genetics.

[82]  G. Evans,et al.  A trithorax–like gene is interrupted by chromosome 11q23 translocations in acute leukaemias , 1992, Nature Genetics.

[83]  J. Rowley,et al.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S. A. Ganai.  Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy. , 2016, Current topics in medicinal chemistry.

[85]  T. Kundu,et al.  Chromatin organization, epigenetics and differentiation: an evolutionary perspective. , 2013, Sub-cellular biochemistry.

[86]  L. Vassilev,et al.  Small-molecule inhibitors of the p53-MDM2 interaction. , 2011, Current topics in microbiology and immunology.